9 news items
Takeda Presents Phase 2b Results for Narcolepsy Treatment at SLEEP 2024
TAK
3 Jun 24
2024, the 38th annual meeting of the American Academy of Sleep Medicine and the Sleep Research Society. TAK-861 is an investigational oral orexin
Takeda's TAK-861 Phase 2b Late-Breaking Data Presentations at SLEEP 2024 Demonstrate Clinically Meaningful Impact of Oral Orexin Agonist in Narcolepsy Type 1 Compared to Placebo
TAK
3 Jun 24
is an investigational oral orexin receptor 2 (OX2R) agonist and, based on the results, has the potential to provide transformative efficacy in addressing the overall
Takeda Receives Positive CHMP Opinion for Recombinant ADAMTS13 (rADAMTS13) in Congenital Thrombotic Thrombocytopenic Purpura (cTTP)
TAK
31 May 24
. rADAMTS13 is also being investigated in adults with immune-mediated thrombotic thrombocytopenic purpura (iTTP), the acquired form of TTP, in an ongoing
Why Is Small-Cap Alzheimer's-Focused AC Immune Stock Trading Higher On Monday?
ACIU
TAK
13 May 24
has the potential to delay or slow Alzheimer’s disease progression.
ACI-24.060 is being investigated in the ongoing
AC Immune and Takeda Sign Exclusive Option and License Agreement for Active Immunotherapy Targeting Amyloid Beta for Alzheimer's Disease
ACIU
TAK
13 May 24
inhibiting plaque formation in the brain, ACI-24.060 has the potential to delay or slow Alzheimer's disease progression. ACI-24.060 is being investigated
shf5w5r13vokb ze
ACIU
TAK
13 May 24
investigated in the ongoing ABATE randomized, double-blind, placebo-controlled Phase 1b/2 trial to assess the safety, tolerability, immunogenicity
tnpwabonts0m978g4pl2edshb9w11ppwns ryqrrgxlnyy5wdtl0x21qlnfh
TAK
26 Apr 24
investigated fruquintinib plus best supportive care (BSC) versus placebo plus BSC in patients with previously treated mCRC. FRESCO-2 met all its primary
ssv8ype44hn2cnmc47fj66qavwodcp3esa7hl6a2a78vythgq55vqc
TAK
26 Apr 24
investigated fruquintinib plus best supportive care (BSC) versus placebo plus BSC in patients with previously treated mCRC. FRESCO-2 met all its primary
7o85wvm1xp9en8qeefbrz5pho3qov01enhjpx4rpe5kdri0a8fif3ldz
TAK
19 Mar 24
Anderson Cancer Center and lead investigator of the PhALLCON trial. "Ponatinib may help address these factors and impact long-term outcomes."ICLUSIG
- Prev
- 1
- Next